You just read:

Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease

News provided by

Neuraltus Pharmaceuticals, Inc.

Dec 03, 2010, 07:30 EST